Literature DB >> 31901932

Differences in Functional Connectivity Networks Related to the Midbrain Dopaminergic System-Related Area in Various Psychiatric Disorders.

Yuko Nakamura1,2, Naohiro Okada3,4, Daisuke Koshiyama3, Kouhei Kamiya5, Osamu Abe5, Akira Kunimatsu5,6, Kazuo Okanoya1,2,4,7, Kiyoto Kasai1,2,3,4,7, Shinsuke Koike1,2,3,4,7.   

Abstract

OBJECTIVE: Disruptions in the dopamine system have been observed in psychiatric disorders. Since dopamine is mainly produced in the ventral tegmental area (VTA), elucidating the differences in the VTA neural network across psychiatric disorders would facilitate a greater understanding of the pathophysiological mechanisms underlying these disorders. However, no study has compared VTA-seed-based functional connectivity across psychiatric disorders. Therefore, we conducted a resting-state functional magnetic resonance imaging (rs-fMRI) study to perform a seed-based fMRI analysis, using the VTA as a seed.
METHODS: We included participants with major depressive disorder (MDD; n = 45), schizophrenia (n = 32), and bipolar disorder (BPD; n = 30), along with healthy control participants (n = 46) who were matched for age, gender, and handedness.
RESULTS: The results showed that patients with MDD and BPD had altered VTA-related connectivity in the superior frontal gyrus, frontal pole regions, hippocampus, cerebellum, and posterior cingulate cortex. Some of these differences in connectivity were also found between affective disorders and schizophrenia; however, there were no differences between the schizophrenia and control groups. Connectivity between the VTA and the hippocampus was correlated with positive symptoms in the schizophrenia group. The connectivity was not associated with medication dose, and the results remained significant after controlling for dose.
CONCLUSIONS: The results suggest that altered brain functional connectivity related to VTA networks could be associated with the distinctive pathophysiologies of psychiatric disorders, especially affective disorders.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  psychiatric disorders; resting-state functional magnetic resonance imaging; the ventral tegmental area

Year:  2020        PMID: 31901932      PMCID: PMC7505191          DOI: 10.1093/schbul/sbz121

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  64 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview.

Authors:  Tempei Otsubo; Katsutoshi Tanaka; Rumiko Koda; Junko Shinoda; Nana Sano; Satoshi Tanaka; Hiroshi Aoyama; Masaru Mimura; Kunitoshi Kamijima
Journal:  Psychiatry Clin Neurosci       Date:  2005-10       Impact factor: 5.188

3.  Neural basis of autobiographical memory retrieval in schizophrenia.

Authors:  Christine Cuervo-Lombard; Cédric Lemogne; Fabien Gierski; Céline Béra-Potelle; Eric Tran; Christophe Portefaix; Arthur Kaladjian; Laurent Pierot; Frédéric Limosin
Journal:  Br J Psychiatry       Date:  2012-04-26       Impact factor: 9.319

Review 4.  Organization of dopamine and serotonin system: Anatomical and functional mapping of monosynaptic inputs using rabies virus.

Authors:  Sachie K Ogawa; Mitsuko Watabe-Uchida
Journal:  Pharmacol Biochem Behav       Date:  2017-05-02       Impact factor: 3.533

5.  Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder.

Authors:  Virginie Sterpenich; Sonia Vidal; Jeremy Hofmeister; Giorgio Michalopoulos; Victor Bancila; Delphine Warrot; Alexandre Dayer; Martin Desseilles; Jean-Michel Aubry; Markus Kosel; Sophie Schwartz; Laszlo Vutskits
Journal:  Anesthesiology       Date:  2019-06       Impact factor: 7.892

6.  Shedding light on the role of ventral tegmental area dopamine in reward.

Authors:  Benjamin T Saunders; Jocelyn M Richard
Journal:  J Neurosci       Date:  2011-12-14       Impact factor: 6.167

7.  Investigating the Impact of a Genome-Wide Supported Bipolar Risk Variant of MAD1L1 on the Human Reward System.

Authors:  Sarah Trost; Esther K Diekhof; Holger Mohr; Henning Vieker; Bernd Krämer; Claudia Wolf; Maria Keil; Peter Dechent; Elisabeth B Binder; Oliver Gruber
Journal:  Neuropsychopharmacology       Date:  2016-05-13       Impact factor: 7.853

Review 8.  Dopamine hypothesis of schizophrenia: making sense of it all.

Authors:  Mitsuru Toda; Anissa Abi-Dargham
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

9.  Shared and Distinct Functional Architectures of Brain Networks Across Psychiatric Disorders.

Authors:  Mingrui Xia; Fay Y Womer; Miao Chang; Yue Zhu; Qian Zhou; Elliot Kale Edmiston; Xiaowei Jiang; Shengnan Wei; Jia Duan; Ke Xu; Yanqing Tang; Yong He; Fei Wang
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

Review 10.  The brain reward circuitry in mood disorders.

Authors:  Scott J Russo; Eric J Nestler
Journal:  Nat Rev Neurosci       Date:  2013-08-14       Impact factor: 34.870

View more
  3 in total

1.  Functional Coupling within the Mesolimbic Circuit in First-Episode Psychosis.

Authors:  Or Duek
Journal:  eNeuro       Date:  2021-04-29

2.  Increased Functional Coupling between VTA and Hippocampus during Rest in First-Episode Psychosis.

Authors:  David F Gregory; Jane M Rothrock; Maria Jalbrzikowski; William Foran; David F Montez; Beatriz Luna; Vishnu P Murty
Journal:  eNeuro       Date:  2021-03-18

Review 3.  Magnetic resonance imaging of the dopamine system in schizophrenia - A scoping review.

Authors:  Julia Schulz; Juliana Zimmermann; Christian Sorg; Aurore Menegaux; Felix Brandl
Journal:  Front Psychiatry       Date:  2022-09-20       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.